A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients

Hüser, Christoph; Dieterich, Pauline; Singh, Jaswinder; Shah‐Hosseini, Kija; Allekotte, Silke; Lehmacher, Walter; Compalati, E; Mösges, Ralph

doi:10.1111/all.12913

Cited by 19 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allergoids, recombinant hypoallergens, immunogenic allergen peptides, adjuvants that are stimulators of innate immune system, allergens fused with immune modifiers and peptide transporting proteins are among these efforts . Trials investigating grass, ragweed, tree pollen, and house dust mite allergoid utilization in AIT have revealed success . Alternative routes for administration of AIT allergens have been projected for improvement of both safety and efficacy.…”

Section: An Overview Of Allergen‐specific Immunotherapy Mechanismsmentioning

confidence: 99%

Allergen Immunotherapy in Children User’s Guide

Alvaro‐Lozano

Akdiş

Alviani

et al. 2020

Pediatric Allergy Immunology

192

240

View full text Add to dashboard Cite

Aim and scopePediatric Allergy and Immunology publishes original contributions and comprehensive reviews related to the understanding and treatment of immune defi ciency, allergic infl ammatory and infectious diseases in children. Other areas of interest include development of specifi c and accessory immunity, and the immunological interaction during pregnancy and lactation between mother and child. As the journal is intended to promote communication between scientists engaged in basic research and clinicians working with children, both clinical and experimental work will be published.

show abstract

Section: An Overview Of Allergen‐specific Immunotherapy Mechanismsmentioning

confidence: 99%

Allergen Immunotherapy in Children User’s Guide

Alvaro‐Lozano

Akdiş

Alviani

et al. 2020

Pediatric Allergy Immunology

192

240

View full text Add to dashboard Cite

show abstract

“…It may also serve as a carrier of bacteria responsible for the induction of IgE sensitization to microbial antigens . Patients allergic to HDM can be successfully treated with HDM AIT . HDM‐reactive IL‐5 + IL‐13 + CD27 − CD161 + CD4 + cells and ST2 + CD45RO + CD4 + cells were significantly lower in active responders to HDM sublingual immunotherapy .…”

Section: Introductionmentioning

confidence: 99%

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Boonpiyathad

Sokołowska

Morita

et al. 2019

Allergy

View full text Add to dashboard Cite

Background: Allergen-specific immunotherapy (AIT) is the only available treatment for allergic diseases that can induce specific immune tolerance to allergens. The key mechanisms involved in this process include changes in allergen-specific regulatory T (Treg) cells. Methods:We studied 25 allergic rhinitis patients undergoing subcutaneous house dust mite-specific immunotherapy. Peripheral blood mononuclear cells were studied before and after 10, 30 weeks, and 3 years of AIT. Der p 1-specific T regulatory cell responses were investigated by characterization of Der p 1-MHC class II tetramerpositive cells and correlated with nasal symptom score. Results: Twelve of 25 AIT patients matched with their MHC class II expression to the Der p 1 peptide-MHC class II tetramers. A significant increase in the numbers of Der p 1-specific FOXP3 + Helios + CD25 + CD127 − Treg cells after 30 weeks was observed, which slightly decreased after 3 years of AIT. In contrast, Der p 1-specific immunoglobulin-like transcript 3 (ILT3) + CD25 + Treg cells decreased substantially from baseline after 3 years of AIT. ILT3 + Treg cells displayed compromised suppressive function and low FOXP3 expression. In addition, Der p 1-specific IL-10 and IL-22 responses have increased after 30 weeks, but only IL-10 + Der p 1-specific Treg cells remained present at high frequency after 3 years of AIT. Increased number of FOXP3 + Helios + and IL-10 + and decreased ILT3 + Treg cell responses correlated with improved allergic symptoms. Conclusion: The results indicate that AIT involves upregulation of the activated allergen-specific Treg cells and downregulation of dysfunctional allergen-specific Treg cell subset. Correction of dysregulated Treg cells responses during AIT is associated with improved clinical response. K E Y W O R D Sallergen-specific T cells, antigen-specific immunotherapy, house dust mite allergy, Treg Abbreviations: AIT, antigen-specific immunotherapy; AR, allergic rhinitis; HDM, house dust mite; ILT3, immunoglobulin-like transcript 3; Treg, T regulatory.

show abstract

“…Jutel et al1 were unable to demonstrate significantly different CPT results between placebo and actively treated groups, with 53.8% of the placebo group patients having higher CPT response thresholds. Hüser et al29 reported the highest number: 64.3% of placebo group patients showed reduced post‐treatment CPT reactivity. Composite scores confirmed that no desensitization occurred in the placebo group of our study.…”

Section: Discussionmentioning

confidence: 97%

A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy

Mösges

Kasche

Raskopf

et al. 2017

Allergy

Self Cite

View full text Add to dashboard Cite

BackgroundA novel subcutaneous allergen immunotherapy formulation (gpASIT+™) containing Lolium perenne peptides (LPP) and having a short up‐dosing phase has been developed to treat grass pollen–induced seasonal allergic rhinoconjunctivitis. We investigated peptide immunotherapy containing the hydrolysate from perennial ryegrass allergens for the optimum dose in terms of clinical efficacy, immunogenicity and safety.MethodsThis prospective, double‐blind, placebo‐controlled, phase IIb, parallel, four‐arm, dose‐finding study randomized 198 grass pollen–allergic adults to receive placebo or cumulative doses of 70, 170 or 370 μg LPP. All patients received weekly subcutaneous injections, with the active treatment groups reaching assigned doses within 2, 3 and 4 weeks, respectively. Efficacy was assessed by comparing conjunctival provocation test (CPT) reactions at baseline, after 4 weeks and after completion. Grass pollen–specific immunoglobulins were analysed before and after treatment.ResultsConjunctival provocation test (CPT) response thresholds improved from baseline to V7 by at least one concentration step in 51.2% (170 μg; P = .023), 46.3% (370 μg), and 38.6% (70 μg) of patients receiving LPP vs 25.6% of patients receiving placebo (modified per‐protocol set). Also, 39% of patients in the 170‐μg group became nonreactive to CPT vs 18% in the placebo group. Facilitated allergen‐binding assays revealed a highly significant (P < .001) dose‐dependent reduction in IgE allergen binding across all treatment groups (70 μg: 17.1%; 170 μg: 18.8%; 370 μg: 26.4%). Specific IgG4 levels increased to 1.6‐fold (70 μg), 3.1‐fold (170 μg) and 3.9‐fold (370 μg) (mPP).ConclusionThree‐week immunotherapy with 170 μg LPP reduced CPT reactivity significantly and increased protective specific antibodies.

show abstract

A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients

Cited by 19 publications

References 24 publications

Allergen Immunotherapy in Children User’s Guide

Allergen Immunotherapy in Children User’s Guide

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy

Contact Info

Product

Resources

About